Translational PET Imaging of Nectin-4 Expression in Multiple Different Cancers with 68 Ga-N188

作者：Jianhua Zhang, Xiaojiang Duan, Xueqi Chen, Zhuochen Zhang, Hongwei Sun, Jiayin Shou, Guangyu Zhao, Jianxin Wang, Yongsu Ma, Yinmo Yang, Xiaodong Tian, Qi Shen, Wei Yu, Zhisong He, Yan Fan, Xing Yang · 发表于：Journal of Nuclear Medicine · 年份：2024 · DOI：10.2967/jnumed.123.266830 · 被引用次数：36 · 研究领域：Urinary and Genital Oncology Studies、Bladder and Urothelial Cancer Treatments、Urologic and reproductive health conditions

Nectin cell adhesion molecule 4 (nectin-4) is a transmembrane protein overexpressed on a variety of cancers and plays an important role in oncogenic and metastatic processes. The nectin-4–targeted antibody–drug conjugate enfortumab vedotin has been approved for treating locally advanced or metastatic urothelial cancer, but the efficacy in other types of cancer remains to be explored. The aim of this study was to evaluate the feasibility of nectin-4–targeted PET imaging with 68 Ga-N188 as a noninvasive method to quantify membranous nectin-4 expression in multiple tumor types—an approach that may provide insight for patient stratification and treatment selection. Methods: Sixty-two patients with 16 types of cancer underwent head-to-head 68 Ga-N188 and 18 F-FDG PET/CT imaging for initial staging or detection of recurrence and metastases. Correlation between lesion SUV max and nectin-4 expression determined by immunohistochemistry staining was analyzed in 36 of 62 patients. Results: The SUV max of 68 Ga-N188 had a positive correlation with membranous nectin-4 expression in the various tumor types tested ( r = 0.458; P = 0.005), whereas no association was observed between the SUV max and cytoplasmic nectin-4 expression. The detection rates for patient-based analysis of 68 Ga-N188 and 18 F-FDG PET/CT examinations were comparable (95.00% [57/60] vs. 93.33% [56/60]). In patients with pancreatic cancer, 68 Ga-N188 exhibited a potential advantage for detecting residual...